Can a lower drug dose prevent transplant complications just as well?

NCT ID NCT06705062

Recruiting now Disease control Sponsor: Shanghai Jiao Tong University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a lower dose of the drug cyclophosphamide can prevent graft-versus-host disease (GVHD) after stem cell transplants from unrelated or half-matched donors. About 316 participants will receive either a reduced dose (35 mg/kg) or the standard dose (50 mg/kg), along with other immune-suppressing drugs. The goal is to see if the lower dose works as well but causes fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cyclophosphamide (reduced dose 35 mg/kg vs standard 50 mg/kg), tacrolimus, and anti-thymocyte globulin
What this could lead to: If successful, this could offer a safer way to prevent graft-versus-host disease after stem cell transplants, with fewer side effects and similar protection.
What could go wrong: This is a phase 3 trial, but the reduced dose may not prevent GVHD as well as the standard dose. Results may not apply to all transplant types or patient groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

graft versus host disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANT GRAFT-VERSUS-HOST DISEASE

Contacts and locations

Locations

Ruijin hsopital
RECRUITING

Shanghai, Shanghai Municipality, 200025, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.